Know the Latest About COVID-19 Monoclonal Antibodies
August 2021
Recent evidence and rising cases will renew focus on COVID-19 monoclonal antibodies...casirivimab/imdevimab (Regen-COV), etc.
Patients. Early data now suggest casirivimab/imdevimab reduces mortality in patients HOSPITALIZED due to COVID-19.
But it's not authorized for these patients yet...and the dose showing benefit is over 6 times the current authorized dose.
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote